RARE Stock UPDATES Ultragenyx Pharmaceutical Inc. (RARE) 56.34

New Post Public Reply Private Reply Replies (0) Message Board

Sep 16, 2014 at 8:12 PM

Ultragenyx Pharmaceutical Inc. (RARE) 56.34 $RARE

IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.

Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.

Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Wed Sep 03, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Innsbruck, Austria.

Ultragenyx to Present at the Baird Health Care Conference
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Robert W. Baird & Co. 2014 Health Care Conference on September 3, 2014 at 1:45pm ET in New York.

3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Tue Aug 26, 6:00AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:41AM CDT
Ultragenyx (RARE) Shares March Higher, Can It Continue?

Company News for August 12, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:10AM CDT
Companies in the News are: DF,SYY,VHI,RARE

Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the second quarter ended June 30, 2014.

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

Why Ultragenyx Pharmaceutical (RARE) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 7:30AM CDT
Ultragenyx Pharmaceutical (RARE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 06, 8:04AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Wedbush PacGrow Life Sciences Management Access Conference on August 13, 2014 at 3:40pm ET in New York and at the Canaccord Genuity Growth Conference on August 14, 2014 at 10:30am ET in Boston.

Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
GlobeNewswire - Tue Aug 05, 8:01AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin (UX007). The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland.

Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.

3 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 31, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President
GlobeNewswire - Wed Jul 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's CEO, and will serve on the Senior Management Team.

Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.

Ultragenyx concludes public offering of 2.32m common shares, including exercise of underwriters' option
M2 - Tue Jul 15, 8:19AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) revealed on Monday the completion of its public offering of 2,319,951 shares of common stock.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...